Covidien Stock To Go Ex-dividend Tomorrow (COV)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Covidien (NYSE: COV) is tomorrow, April 2, 2013. Owners of shares as of market close today will be eligible for a dividend of 26 cents per share. At a price of $67.68 as of 9:30 a.m. ET, the dividend yield is 1.5%.

The average volume for Covidien has been 2.2 million shares per day over the past 30 days. Covidien has a market cap of $32.02 billion and is part of the health care sector and health services industry. Shares are up 17.5% year to date as of the close of trading on Thursday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Covidien Ratings Report.

See our dividend calendar or top-yielding stocks list.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback